At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BMEA Biomea Fusion, Inc.
Pre-Mkt 10-13 04:20:20 EDT
1.36
-0.06
-4.23%
盘前1.46
+0.10+7.37%
04:19 EDT
High1.46Low1.36Vol5.37M
Open1.44D1 Closing1.42Amplitude7.04%
Mkt Cap98.33MTradable Cap94.77MTotal Shares72.30M
T/O7.50MT/O Rate7.70%Tradable Shares69.69M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Biomea Fusion to Release Phase I Results for Oral GLP-1 Agonist BMF-650 on Oct. 13
Reuters  ·  04:31
Biomea Fusion to Release Phase I Results for Oral GLP-1 Agonist BMF-650 on Oct. 13
Biomea Fusion to Announce Phase I Results for Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
THOMSON REUTERS  ·  04:30
Biomea Fusion to Announce Phase I Results for Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Biomea Fusion Price Target Announced at $10.00/Share by Brookline Capital
Dow Jones  ·  10-07
Biomea Fusion Price Target Announced at $10.00/Share by Brookline Capital
Biomea Fusion Shares Fall After Terminating Proposed Public Offering
MT Newswires Live  ·  09-24
Biomea Fusion Shares Fall After Terminating Proposed Public Offering
Biomea Fusion Completes Phase 1 BMF-500 Trial in Acute Leukemia: What Investors Should Watch Next
TIPRANKS  ·  09-24
Biomea Fusion Completes Phase 1 BMF-500 Trial in Acute Leukemia: What Investors Should Watch Next
Biomea Fusion Updates Timeline for BMF-650 Phase I Data
TIPRANKS  ·  09-23
Biomea Fusion Updates Timeline for BMF-650 Phase I Data
Biomea Fusion announces offering of common stock and warrants, no amount given
TIPRANKS  ·  09-23
Biomea Fusion announces offering of common stock and warrants, no amount given
Biomea Fusion Launches Underwritten Public Offering of Common Stock, Pre-Funded Warrants
Reuters  ·  09-23
Biomea Fusion Launches Underwritten Public Offering of Common Stock, Pre-Funded Warrants
Biomea Fusion Announces Proposed Public Offering of Securities
THOMSON REUTERS  ·  09-23
Biomea Fusion Announces Proposed Public Offering of Securities
Biomea Fusion - Topline Results from Phase I Glp-131 Trial for Bmf-650 Expected in October 2026 - SEC Filing
THOMSON REUTERS  ·  09-23
Biomea Fusion - Topline Results from Phase I Glp-131 Trial for Bmf-650 Expected in October 2026 - SEC Filing
Biomea Fusion to Participate in Upcoming Investor Conferences
GlobeNewswire  ·  09-03
Biomea Fusion to Participate in Upcoming Investor Conferences
Biomea Fusion Completes Key Phase 2 Trial in Type 1 Diabetes: What Investors Should Watch Next
TIPRANKS  ·  08-29
Biomea Fusion Completes Key Phase 2 Trial in Type 1 Diabetes: What Investors Should Watch Next
Biomea Shares Rise After Completing Enrollment in Diabetes Trial
MT Newswires Live  ·  08-25
Biomea Shares Rise After Completing Enrollment in Diabetes Trial
Unusually active option classes on open August 24th
TIPRANKS  ·  08-24
Unusually active option classes on open August 24th
Biomea Fusion completes enrollment in COVALENT-211 trial
TIPRANKS  ·  08-24
Biomea Fusion completes enrollment in COVALENT-211 trial
Biomea Fusion, - Topline 26-Week Primary Endpoint Data from Covalent-211 Expected in Q1 2027
THOMSON REUTERS  ·  08-24
Biomea Fusion, - Topline 26-Week Primary Endpoint Data from Covalent-211 Expected in Q1 2027
Biomea Fusion Announces Completion of Enrollment in Covalent-211 Phase Ii Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
THOMSON REUTERS  ·  08-24
Biomea Fusion Announces Completion of Enrollment in Covalent-211 Phase Ii Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
Biomea Fusion doses first patient in OPAL study
TIPRANKS  ·  08-17
Biomea Fusion doses first patient in OPAL study
Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB) and Biomea Fusion (BMEA)
TIPRANKS  ·  08-13
Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB) and Biomea Fusion (BMEA)
Biomea Fusion Doses First Patient in OPAL Trial of Icovamenib Plus Semaglutide for Obesity
Reuters  ·  08-13
Biomea Fusion Doses First Patient in OPAL Trial of Icovamenib Plus Semaglutide for Obesity

Introduction

Company Name.
Biomea Fusion, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Issue price:
--